Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Receives grant award from the Bill & Melinda Gates Foundation in the amount of $9.0M for the development of tuberculosis test on Co-Dx™ PCR platform.
SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ — Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023.
Related news for (CODX)
- Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia
- Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
- Power Hour Watchlist: AI Pops, Crypto Climbs, and Small Cap Names Heating Up
- MoBot alert highlights: NASDAQ: CDLX, NASDAQ: ILLR, NASDAQ: TURB, NASDAQ: CODX, NASDAQ: CCG (09/16/25 11:00 AM)
- Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
